Epizyme

EPZM NASDAQ
15.54
+0.57
+3.81%
交易中 14:04 06/24 EDT
开盘
15.00
昨收
14.97
最高
16.59
最低
14.91
成交量
117.40万
成交均量(3M)
77.08万
52周最高
16.59
52周最低
5.14
换手率
1.29%
市值
14.12亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Epizyme EPZM股票价格,Epizyme股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
展开 >

最近浏览

名称
价格
涨跌幅